Time and Effort Required for Tissue Acquisition and Submission in Lung Cancer Clinical Trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Time and Effort Required for Tissue Acquisition and Submission in Lung Cancer Clinical Trials

Published:2017-11 Issue:6 Volume:18 Page:626-630
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Garcia Sandra,Saltarski Jessica M.,Yan Jingsheng,Xie Xian-Jin,Gerber David E.

Funder

National Cancer Institute

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference20 articles.

1. The ethical use of mandatory research biopsies;Olson;Nat Rev Clin Oncol,2011

2. Patients with advanced non–small cell lung cancer: are research biopsies a barrier to participation in clinical trials?;Lim;J Thorac Oncol,2016

3. Identification of cancer care and protocol characteristics associated with recruitment in breast cancer clinical trials;Lemieux;J Clin Oncol,2008

4. Cancer patient accessions into clinical trials: a pilot investigation into some patient and physician determinants of entry;McCusker;Am J Clin Oncol,1982

5. Reasons for non-entry in randomized clinical trials for breast cancer: a single institutional study;Kotwall;J Surg Oncol,1992

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transferring care to enhance access to early-phase cancer clinical trials: Protocol to evaluate a novel program;Contemporary Clinical Trials Communications;2024-06

2. Streamlining clinical research: an ESMO awareness call to improve sponsoring and monitoring of clinical trials;Annals of Oncology;2023-01

3. Enhancing access to and diversity in cancer clinical trials through a financial reimbursement program: Protocol to evaluate a novel program;Contemporary Clinical Trials;2022-10

4. Clinical trial cytology: Use of on-site evaluation of small biopsy and FNA samples for clinical trials and biomarker research studies;Cancer Cytopathology;2018-05-02

5. Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer;Lung Cancer;2018-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3